Multicenter, Randomized, Open-Label Study to Evaluate AT-1501 in Patients Undergoing Kidney Transplant
Status:
Not yet recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, open-label, active control, non-inferiority study to
assess the safety and efficacy of AT-1501 compared with tacrolimus in the incidence of BPAR
events through 6 months post-transplant.